Atomwise

Atomwise pioneered the use of deep convolutional neural networks for structure-based drug discovery, with its AtomNet platform applying AI to virtual screening of small molecules against protein targets. The company ran the Artificial Intelligence Molecular Screen (AIMS) academic collaboration program, partnered with biotech and pharma companies on discovery contracts, and built an internal pipeline of small-molecule programs. As of 2026, atomwise.com redirects to Numerion Labs (numerionlabs.ai), reflecting an apparent rebrand or successor entity that positions itself as an AI superplatform exploring drug-like chemical space with programs in immune and inflammatory diseases. Atomwise never exposed a public commercial API; AtomNet screening was delivered to partners as a service. The legacy GitHub organization (github.com/atomwise) hosts no public repositories.

Atomwise is profiled on the APIs.io network. Tagged areas include Drug Discovery, Biotech, Pharmaceuticals, Structure-Based Drug Design, and Virtual Screening.

🌐 Visit website 📡 Source on GitHub

5.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0

0 APIs

Drug Discovery Biotech PharmaceuticalsStructure-Based Drug DesignVirtual ScreeningDeep LearningConvolutional Neural NetworksAtomNetSmall Molecules CheminformaticsAIMS ProgramNumerion Labs

Kin Score

Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0

Composite quality — 5.3/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Access Clarity 0.0 / 20

Operational Transparency 0.3 / 13

Contract Governance 0.0 / 12

Discoverability 5.0 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/atomwise: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Atomwise Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 4

The organization behind the API

Website

Website

LinkedIn

Twitter

Twitter

Crunchbase

Crunchbase

Other 1

Properties that don't map to a standard resource type

Successor

Successor

Source (apis.yml)

aid: atomwise
name: Atomwise
description: Atomwise pioneered the use of deep convolutional neural networks for structure-based drug discovery, with its
  AtomNet platform applying AI to virtual screening of small molecules against protein targets. The company ran the Artificial
  Intelligence Molecular Screen (AIMS) academic collaboration program, partnered with biotech and pharma companies on discovery
  contracts, and built an internal pipeline of small-molecule programs. As of 2026, atomwise.com redirects to Numerion Labs
  (numerionlabs.ai), reflecting an apparent rebrand or successor entity that positions itself as an AI superplatform exploring
  drug-like chemical space with programs in immune and inflammatory diseases. Atomwise never exposed a public commercial API;
  AtomNet screening was delivered to partners as a service. The legacy GitHub organization (github.com/atomwise) hosts no
  public repositories.
type: Index
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - url: https://www.atomwise.com
    status: 301
    note: declared website redirects to https://numerionlabs.ai/ — a different registrable domain (atomwise.com -> numerionlabs.ai),
      possible rename or acquisition (probed 2026-09-03, roadmap#169)
  generated: '2026-07-22'
  method: derived
position: Producing
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/atomwise.png
tags:
- Drug Discovery
- Biotech
- Pharmaceuticals
- Structure-Based Drug Design
- Virtual Screening
- Deep Learning
- Convolutional Neural Networks
- AtomNet
- Small Molecules
- Cheminformatics
- AIMS Program
- Numerion Labs
url: https://raw.githubusercontent.com/api-evangelist/atomwise/refs/heads/main/apis.yml
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
  url: security/atomwise-domain-security.yml
- type: Website
  url: https://www.atomwise.com
- type: Successor
  url: https://numerionlabs.ai
- type: GitHubOrganization
  url: https://github.com/atomwise
- type: LinkedIn
  url: https://www.linkedin.com/company/atomwise-inc-
- type: Twitter
  url: https://twitter.com/AtomwiseInc
- type: Crunchbase
  url: https://www.crunchbase.com/organization/atomwise
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/atomwise"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/atomwise/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/atomwise/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.